ATI-2138 data presented at 2026 AAD Annual Meeting suggest therapeutic potential

Aclaris reported Phase 2a results for ATI-2138 at the 2026 American Academy of Dermatology meeting, stating the 10 mg twice-daily, 12-week regimen was well tolerated and produced a 77% improvement in EASI at week 12.

Aclaris Therapeutics presented additional results from its open-label Phase 2a trial of ATI-2138 in an electronic poster at the 2026 American Academy of Dermatology Annual Meeting. The study evaluated 10 mg of ATI-2138 given twice daily for 12 weeks in patients with moderate-to-severe atopic dermatitis. The company reported that the treatment was well tolerated and produced rapid and sustained improvements in clinical signs and symptoms. The article presents these findings as supporting further investigation of ATI-2138 in immuno-inflammatory diseases. Key findings: - At week 12, patients receiving 10 mg BID of ATI-2138 experienced a 77% improvement in the Eczema Area and Severity Index (EASI). - The article reports improvements in itch, affected body surface area, and disease-related quality of life measures. - ATI-2138 was described as well tolerated with reported rapid and sustained clinical improvements over the 12-week period. - Near complete and sustained ITK target occupancy was observed across the dosing interval, as previously disclosed. - Tape-Strip analyses reported modulation of Th1, Th2, Th17, fibrotic, and T cell activation/immune signaling pathway markers. - The Phase 2a trial was open-label and single-arm, with primary endpoints focused on safety and secondary endpoints including pharmacodynamics and efficacy measures such as EASI and Peak Pruritus NRS. Summary: The reported results indicate clinical improvements and biomarker engagement in this Phase 2a study, which the company presented as supporting further study of ATI-2138. Specific next steps or detailed plans for subsequent trials were mentioned in forward-looking terms but were not detailed; undetermined at this time.